Document:

EX-10.13

 Exhibit 10.13 

NINTH ADDENDUM 
 TO THE
RESEARCH AND LICENSE AGREEMENT 
 This Ninth Addendum to Research and License Agreement (the “Ninth Addendum”) is made by and between
the Technion Research and Development Foundation Ltd. (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Licensee” or “Eloxx”). 

Whereas, TRDF and Eloxx are parties to a Research and License Agreement with an effective date of August
29th, 2013 (the “License Agreement”), as amended on November 26th, 2013, January 14th, 2014, June 9th, 2014, August 3rd, 2014, January 21st, 2015”), February 9th 2015, April 29th, 2015, June 2nd, 2015, January 1st, 2016, March 6th, 2016 and June __, 2017 (collectively, the
“Agreement”); and 
 Whereas, according to Section 1.26 to the License Agreement, as amended, all previous Research Periods
have ended and related Research Plans were all completed respectively; 
 Whereas, the parties desire to extend and continue the Research Period and
the Research for a fourth year; and 
 Whereas, the parties desire to continue the relationship contemplated by the Agreement and therefore to
further amend the Agreement as set forth herein; 
 NOW, THEREFORE, the parties hereby agree as follows: 

 

	1.	Unless otherwise defined herein, capitalized terms used in this Seventh Addendum shall have the meaning assigned thereto in the Agreement. 

 

	2.	The parties wish to extend the Research Period for a fourth year, commencing on May 1st 2017 for twelve (12) months until April 30th, 2018 (“Fourth Research Period”). The extension shall be on the same terms and conditions as contained in the Agreement unless otherwise agreed in this Seventh Addendum.

  

	3.	Exhibit D to the Agreement is hereby replaced with a new Exhibit D attached hereto (“Fourth Research Plan”). 

  

	4.	The parties wish to set the terms for the funding for the performance of the Fourth Research Plan during the Fourth Research Period, and replace section 2.2.1 of the License Agreement, as follows: 

 

	 	a)	Licensee shall fund the Research to be performed during the Fourth Research Period under the Fourth Research Plan in the total amount of fifty thousand US Dollars ($50,000) in accordance with the following schedule:

  

	 	1)	First installment of twenty thousand US Dollars ($25,000) shall be paid upon signing this Ninth Addendum. 

  

	 	2)	Second installment of twenty thousand US Dollars ($25,000) shall be paid upon completion of the Fourth Research Plan and no later than April 30th, 2018.

  

	 	b)	V.A.T as applicable on time of payment shall be added to each installment. 

  

	 	c)	TRDF shall issue a proper invoice for each installment. 

	5.	Except as amended herein, all other terms and conditions of the Agreement shall remain in full force and effect. 

  

							
	ELOXX PHARMACEUTICALS LTD.	    	THE TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD.
				
	By:	  	 /s/ Silvia Noiman
	    	By:	  	 /s/ Rita Bruckstein

	Name:	  	Dr. Silvia Noiman, CEO	    	Name:	  	/s/ Rita Bruckstein
	Date:	  	July 16, 2017	    	Date:	  	07-12-2017

  
 2EX-10.15

 Exhibit 10.15 

MEMORANDUM OF UNDERSTANDING 

This Memorandum of Understanding (“Agreement”) is made by and between Silvia Noiman (“Noiman”) and Eloxx Pharmaceuticals
(the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). 

WHEREAS, Noiman entered into a Consulting and Services Agreement with the Company dated October 15, 2013 (“First Consulting
Agreement”); 
 WHEREAS, Noiman entered into a Consulting and Services Agreement with the Company dated December 1, 2014
(“Second Consulting Agreement”); 
 WHEREAS, Noiman entered into an Amendment to Consulting and Services Agreement with the
Company dated January 11, 2017 (“Amendment”); 
 WHEREAS, the Company and Noiman have entered into Stock Option Agreements
for option grants dated April 2014, November 2014, January 2016, and July 2017 granting Noiman options to purchase shares of the Company’s common stock (collectively, the “Option”) subject to the terms and conditions of the
Company’s Share Ownership and Option Plan (2013) and the Stock Option Agreements (collectively the “Stock Agreements”); 

WHEREAS, the Company terminated it service relationship with Noiman, other than as a member of the Board of Directors, effective
January 15, 2018, including but not limited to under the First Consulting Agreement, Second Consulting Agreement, and Amendment; and 

NOW, THEREFORE, in consideration of the mutual promises made herein, the Company and Noiman hereby agree as follows: 

1. Consideration. In consideration of Noiman’ s execution of this Agreement and Noiman’s fulfillment of all of its terms and
conditions, the Company agrees as follows: 
 a. Payment. The Company agrees to pay Noiman a lump sum total of Nine Hundred Thousand
New Israeli Shekels (900,000 NIS), provided within ten (10) business days after the Effective Date ofthis Agreement. Noiman shall issue a valid tax invoice and receipt to the Company upon receipt of the payment hereunder. Noiman shall be solely
responsible to pay all taxes, levies, social benefits, insurance payments and any other payments required by law due in connection with this Agreement and payments hereunder. 

b. Equity Incentive Grants. The Parties agree that they have reached an agreement pursuant to which it will be recommended to the
Company’s Board of Directors that the Company grant Noiman a fully vested option to purchase 141,389 shares of the Company’s common stock and 141,389 fully vested shares of the Company’s common stock as soon as practicable after the
Company’s adoption of its 2018 Equity Incentive Plan, with stock option grant to be priced as of the closing price on the date of grant thereof. Such awards shall be subject to this Agreement becoming effective and Noiman continuous service as
a Director through such grant date. 
 2. Stock Option Vesting. Notwithstanding the termination of the consulting relationship
between the Parties, including termination of the First Consulting Agreement, Second Consulting Agreement, and Amendment, the Parties agree that Noiman shall continue to vest in any existing Stock Option agreements during such time that Noiman is a
Director. All other terms regarding Stock Options in the First, Second and Amendment shall remain unchanged. 
 3. Release of Claims.
Noiman agrees to waive any notice of termination or payment in lieu thereof required under the First Consulting Agreement, Second Consulting Agreement, or Amendment, or any agreement with the Company. Noiman agrees that the foregoing consideration
represents settlement in full of all outstanding obligations owed to Noiman by the Company and its current and former officers, directors, employees, agents, investors, attorneys, shareholders, administrators, affiliates, benefit plans, plan
administrators, professional employer organization or co-employer, insurers, trustees, divisions, and subsidiaries, and predecessor and successor corporations and assigns (collectively, the
“Releasees”). Noiman, on Noiman’s own behalf and on behalf of Noiman’s respective heirs, family members, executors, agents, and assigns, hereby and forever releases the Releasees from, and agrees not to sue concerning, or in any
manner to institute, prosecute, or pursue, any claim, complaint, 

  
 Page 1 of 2 

 
charge, duty, obligation, demand, or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Noiman may possess against any of the
Releasees arising from any omissions, acts, facts, or damages that have occurred up until and including the Effective Date of this Agreement. Noiman agrees that the release set forth in this section shall be and remain in effect in all respects as a
complete general release as to the matters released. This release does not extend to any obligations incurred under this Agreement. This release does not release claims that cannot be released as a matter of law. Noiman represents that Noiman has
made no assignment or transfer of any right, claim, complaint, charge, duty, obligation, demand, cause of action, or other matter waived or released by this Section. 

4. Effective Date. This Agreement will become effective on the date it has been signed by both Parties (the “Effective
Date”). 
 5. Governing Law. This Agreement shall be governed by the laws of the Commonwealth of Massachusetts, without regard
for choice-of-law provisions. Employee consents to personal and exclusive jurisdiction and venue in the Commonwealth of Massachusetts. 

6. Entire Agreement. This Agreement represents the entire agreement and understanding between the Company and Employee concerning the
subject matter of this Agreement and Employee’s employment with and separation from the Company and the events leading thereto and associated therewith, and supersedes and replaces any and all prior agreements and understandings concerning the
subject matter of this Agreement and Employee’s relationship with the Company, including the Amendment, with the exception of Sections 4, 5, 6, 8, and 9 of both the First Consulting Agreement and Second Consulting Agreement, and the Stock
Agreements. 
 7. Voluntary Execution of Agreement. Noiman understands and agrees that Noiman executed this Agreement voluntarily,
without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Noirnan’ s claims against the Company and any of the other Releasees. Noiman acknowledges that: 

 

	 	(a)	Noiman has read this Agreement; 

  

	 	(b)	Noiman has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of Noiman’s own choice or has elected not to retain legal counsel; 

 

	 	(c)	Noiman understands the terms and consequences of this Agreement and of the releases it contains; and 

  

	 	(d)	Noiman is fully aware of the legal and binding effect of this Agreement. 

 IN WITNESS WHEREOF, the Parties have
executed this Agreement on the respective dates set forth below. 
  

			
		  	SILVIA NOIMAN, an individual
		
	Dated: March 13, 2018	  	/s/ Silvia
Noiman                                        
          
		  	Silvia Noiman
		
		  	ELOXX PHARMACEUTICALS
		
	Dated: March 13, 2018	  	By /s/ Robert
Ward                                         
       
		  	      Robert Ward
		  	      Chairman and CEO

  
 Page 2 of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]